糖尿病胃轻瘫治疗市场－全球产业规模、份额、趋势、机会和预测，按类型（2 级、3 级）、按药物类别、按给药途径、按配销通路、按地区和竞争进行细分，2020 年至 2030 年预测

2024 年全球糖尿病胃轻瘫治疗市场价值为 28.9 亿美元，预计到 2030 年将以 3.23% 的复合年增长率稳步增长。该市场致力于糖尿病胃轻瘫的管理，这是一种以胃排空延迟为特征的糖尿病併发症。随着全球糖尿病病例激增，胃轻瘫的盛行率也随之上升，对有效治疗方案的需求也日益增加。根据《Frontiers》杂誌 2025 年的一项研究，5% 至 12% 的糖尿病患者受到胃肠道症状的影响，凸显了改善诊断和治疗方案的必要性。市场涵盖药品、饮食调整和医疗器械，主要产品包括促动力剂、止吐药和营养支持工具。这些治疗方式旨在缓解噁心、呕吐、腹痛和消化不良等症状，最终提高患者的生活品质。对以患者为中心的护理和创新疗法的日益重视继续重塑着不断发展的医疗保健格局。

关键市场驱动因素

糖尿病盛行率上升

主要市场挑战

治疗选择有限

主要市场趋势

个人化医疗

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：全球糖尿病胃轻瘫治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依类型（2级（代偿性胃轻瘫）、3级（胃衰竭））
  • 依药物类别（促胃动力药、止吐药、抗组织胺、其他）
  • 依给药途径（口服、肠胃外、鼻腔）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按类型
  • 按药物类别
  • 依给药途径
  • 按配销通路
  • 按地区

第五章：亚太地区糖尿病胃轻瘫治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型
  • 按药物类别
  • 依给药途径
  • 按配销通路
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第六章：欧洲糖尿病胃轻瘫治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第七章：北美糖尿病胃轻瘫治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第八章：南美洲糖尿病胃轻瘫治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第九章：中东与非洲糖尿病胃轻瘫治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及

第十章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 12 章：全球糖尿病胃轻瘫治疗：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• ANI Pharmaceuticals, Inc.
• Evoke Pharma
• Janssen Pharmaceutica NV
• Teva Pharmaceuticals Inc.
• Pfizer Inc.
• Salix Pharmaceuticals, Inc.
• Allergan
• Novartis AG
• SCHWITZ BIOTECH
• Wellona Pharma

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Diabetic Gastroparesis Treatment Market was valued at USD 2.89 billion in 2024 and is projected to witness steady growth at a CAGR of 3.23% through 2030. This market addresses the management of diabetic gastroparesis, a complication of diabetes marked by delayed stomach emptying. As diabetes cases surge globally, so too does the prevalence of gastroparesis, intensifying the demand for effective treatment options. According to a 2025 study in Frontiers, gastrointestinal symptoms affect 5% to 12% of diabetic individuals, highlighting the need for improved diagnostic and treatment solutions. The market spans pharmaceuticals, dietary modifications, and medical devices, with key products including prokinetic agents, antiemetics, and nutritional support tools. These treatment modalities aim to alleviate symptoms like nausea, vomiting, abdominal pain, and indigestion, ultimately enhancing patients' quality of life. The growing emphasis on patient-centric care and innovative therapies continues to reshape this evolving healthcare landscape.

Key Market Drivers

Rising Prevalence of Diabetes

A significant driver of the Global Diabetic Gastroparesis Treatment Market is the escalating prevalence of diabetes worldwide. Both type 1 and type 2 diabetes have reached alarming levels, with WHO data showing an increase in global diabetes cases from 200 million in 1990 to 830 million in 2022. Among these individuals, approximately 20% experience diabetic gastroparesis due to nerve damage affecting stomach motility. The link between chronic hyperglycemia and gastrointestinal complications means that as diabetes becomes more widespread, so does the incidence of gastroparesis. Notably, in 2022, 14% of adults aged 18+ had diabetes, and over half of diabetic adults aged 30+ remained untreated-particularly in low- and middle-income countries. This growing diabetic population continues to fuel demand for effective treatment options that address gastroparesis symptoms and prevent further complications, positioning this segment as a critical focus within global healthcare.

Key Market Challenges

Limited Treatment Options

Despite progress in managing diabetic gastroparesis, the market still struggles with limited treatment options. The primary drugs used-prokinetic agents and antiemetics-offer only partial relief and are not effective for all patients. This narrow pharmaceutical toolkit leaves many individuals without adequate solutions for persistent symptoms like nausea, bloating, and abdominal pain. The lack of diverse and universally effective medications restricts clinicians' ability to personalize treatment and achieve consistent patient outcomes. Moreover, when standard therapies fail, patients often endure ongoing discomfort, leading to diminished quality of life. Healthcare providers also face difficulty managing a condition that lacks sufficient therapeutic diversity. Addressing this challenge requires greater investment in R&D to develop novel drugs, improve existing formulations, and introduce more targeted treatment approaches capable of catering to a wider range of patient responses.

Key Market Trends

Personalized Medicine

Personalized medicine is gaining momentum in the Global Diabetic Gastroparesis Treatment Market as a transformative trend focused on tailoring treatments to individual patient needs. Since diabetic gastroparesis presents differently across patients, personalization enables more precise and effective symptom management. By factoring in each patient's medical history, symptom severity, and therapeutic response, healthcare providers can optimize treatment strategies-choosing between drug classes like prokinetic agents, antiemetics, or alternative therapies as appropriate. This customized approach improves efficacy, reduces side effects, and enhances patient satisfaction. The rise of personalized medicine underscores a shift toward targeted care, where data-driven decisions and individualized protocols support better health outcomes and address the variability inherent in diabetic gastroparesis cases.

Key Market Players

• ANI Pharmaceuticals, Inc.
• Evoke Pharma
• Janssen Pharmaceutica N.V
• Teva Pharmaceuticals Inc.
• Pfizer Inc.
• Salix Pharmaceuticals, Inc.
• Allergan
• Novartis AG
• SCHWITZ BIOTECH
• Wellona Pharma

Report Scope:

In this report, the Global Diabetic Gastroparesis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Gastroparesis Treatment Market, By Type:

• Grade 2 (Compensated Gastroparesis)
• Grade 3 (Gastric Failure)

Diabetic Gastroparesis Treatment Market, By Route of Administration:

• Oral
• Parenteral
• Nasal

Diabetic Gastroparesis Treatment Market, By Drug Class:

• Gastroprokinetic Agents
• Antiemetic Agents
• Antihistamines
• Others

Diabetic Gastroparesis Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Diabetic Gastroparesis Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Gastroparesis Treatment Market.

Available Customizations:

Global Diabetic Gastroparesis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Diabetic Gastroparesis Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Grade 2(Compensated Gastroparesis), Grade 3(Gastric Failure))
  • 4.2.2. By Drug Class (Gastroprokinetic Agents, Antiemetic Agents, Antihistamines, Others)
  • 4.2.3. By Route of Administration (Oral, Parenteral, Nasal)
  • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Diabetic Gastroparesis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Drug Class
  • 5.2.3. By Route of Administration
  • 5.2.4. By Distribution Channel
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Diabetic Gastroparesis Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Drug Class
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Diabetic Gastroparesis Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Drug Class
      • 5.3.2.2.3. By Route of Administration
      • 5.3.2.2.4. By Distribution Channel
  • 5.3.3. Australia Diabetic Gastroparesis Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Drug Class
      • 5.3.3.2.3. By Route of Administration
      • 5.3.3.2.4. By Distribution Channel
  • 5.3.4. Japan Diabetic Gastroparesis Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Drug Class
      • 5.3.4.2.3. By Route of Administration
      • 5.3.4.2.4. By Distribution Channel
  • 5.3.5. South Korea Diabetic Gastroparesis Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Drug Class
      • 5.3.5.2.3. By Route of Administration
      • 5.3.5.2.4. By Distribution Channel

6. Europe Diabetic Gastroparesis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Diabetic Gastroparesis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Germany Diabetic Gastroparesis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Spain Diabetic Gastroparesis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Italy Diabetic Gastroparesis Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Drug Class
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. United Kingdom Diabetic Gastroparesis Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Drug Class
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By Distribution Channel

7. North America Diabetic Gastroparesis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Diabetic Gastroparesis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Mexico Diabetic Gastroparesis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Canada Diabetic Gastroparesis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel

8. South America Diabetic Gastroparesis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Route of Administration
  • 8.2.5. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Diabetic Gastroparesis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Argentina Diabetic Gastroparesis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Colombia Diabetic Gastroparesis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Diabetic Gastroparesis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Diabetic Gastroparesis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Saudi Arabia Diabetic Gastroparesis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. UAE Diabetic Gastroparesis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel
  • 9.3.4. Egypt Diabetic Gastroparesis Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By Drug Class
      • 9.3.4.2.3. By Route of Administration
      • 9.3.4.2.4. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Diabetic Gastroparesis Treatment: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. ANI Pharmaceuticals, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Evoke Pharma
• 14.3. Janssen Pharmaceutica N.V
• 14.4. Teva Pharmaceuticals Inc.
• 14.5. Pfizer Inc.
• 14.6. Salix Pharmaceuticals, Inc.
• 14.7. Allergan
• 14.8. Novartis AG
• 14.9. SCHWITZ BIOTECH
• 14.10. Wellona Pharma

15. Strategic Recommendations

16. About Us & Disclaimer